

Title: Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431R)

Decision: The Centers for Medicare & Medicaid Services (CMS) is removing the National Coverage Determination (NCD) at §220.6.20, ending coverage with evidence development (CED) for positron emission tomography (PET) beta amyloid imaging and permitting Medicare coverage determinations for PET beta amyloid imaging to be made by the Medicare Administrative Contractors (MACs) under §1862(a)(1)(A) of the Social Security Act (the Act).

What this means: The NCD that is being removed only allowed PET beta amyloid imaging once per lifetime within the context of a clinical trial. With the removal of this NCD, Medicare Administrative Contractors (MACs) will be able to develop their own local coverage determinations for coverage of PET beta amyloid imaging. This service may be covered for members subject to any requirements that may be established by the local MAC and/or HealthPartners.

Effective: October 13, 2023

This announcement can be found at: [Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease \(CAG-00431R\)](#)

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal. HealthPartners UnityPoint Health is a PPO plan with a Medicare contract. Enrollment in HealthPartners UnityPoint Health depends on contract renewal.

H2462_90242 IR Approved 06/2015
H3416_90242 IR Approved 06/2017
H2422_90242 IR Approved 07/2015
H4882_90242 IR Approved 03/2018